Lipocine (NASDAQ:LPCN – Get Free Report) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Friday.
Lipocine Price Performance
NASDAQ LPCN traded up $0.07 during trading on Friday, hitting $4.84. The company’s stock had a trading volume of 17,556 shares, compared to its average volume of 51,227. Lipocine has a fifty-two week low of $2.31 and a fifty-two week high of $11.79. The company has a market cap of $25.88 million, a PE ratio of -2.83 and a beta of 1.21. The business’s 50 day simple moving average is $4.58 and its 200-day simple moving average is $5.52.
Lipocine (NASDAQ:LPCN – Get Free Report) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The company had revenue of $0.09 million for the quarter. Analysts expect that Lipocine will post -0.92 EPS for the current fiscal year.
Institutional Investors Weigh In On Lipocine
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
See Also
- Five stocks we like better than Lipocine
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is the NASDAQ Stock Exchange?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.